600216.SH
浙江医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.55
−5.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.8B | 8.9B | 9.4B | 7.8B | 8.1B |
| Cost of Revenue | 5.9B | 5.8B | 5.4B | 5.3B | 5.3B |
| Gross Profit | 2.9B | 3.1B | 4.0B | 2.5B | 2.8B |
| Operating Expenses | |||||
| R&D Expense | 496.2M | 579.9M | 749.4M | 860.1M | 809.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 552.3M | 520.9M | 586.4M | 445.2M | 432.1M |
| Selling & Marketing Expense | 857.1M | 894.2M | 1.1B | 1.0B | 890.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.0B | 2.0B | 2.5B | 2.4B | 2.2B |
| Cost and Expenses | 7.9B | 7.8B | 7.9B | 7.7B | 7.5B |
| Operating Income (EBIT) | 815.0M | 962.9M | 1.2B | 380.2M | 504.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 804.4M | 951.7M | 1.2B | 363.3M | 491.4M |
| Income Tax Expense | 171.1M | 191.5M | 192.0M | 86.5M | 128.8M |
| Bottom Line | |||||
| Net Income | 751.3M | 873.4M | 1.2B | 429.6M | 539.6M |
| Earnings from Cont. Ops | 633.3M | 760.2M | 1.0B | 276.8M | 362.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 751.3M | 873.4M | 1.2B | 429.6M | 539.6M |
| Per Share | |||||
| Basic EPS | CN¥0.78 | CN¥0.91 | CN¥1.21 | CN¥0.45 | CN¥0.56 |
| Diluted EPS | CN¥0.78 | CN¥0.91 | CN¥1.21 | CN¥0.45 | CN¥0.56 |
| Revenue Per Share | CN¥9.22 | CN¥9.25 | CN¥9.78 | CN¥8.16 | CN¥8.42 |
| Shares | |||||
| Basic Shares Outstanding | 956.7M | 959.8M | 959.1M | 954.8M | 963.5M |
| Diluted Shares Outstanding | 956.7M | 959.8M | 959.1M | 954.8M | 963.5M |
| Profitability Metrics | |||||
| EBITDA | — | 1.8B | 1.9B | 1.1B | 1.2B |
| D&A | — | 797.2M | 725.5M | 726.8M | 684.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026